A citation-based method for searching scientific literature

Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist, Mark M Awad, Geoffrey I Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle A Murphy, Sherry C Wang, Sherry Li, Tiziana Usari, Keith D Wilner, Paul K Paik. Nat Med 2020
Times Cited: 159



Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang, Zhigang Han, Jianhua Shi, Yuan Chen, Hua Xu, Helong Zhang, Gongyan Chen, Rui Ma, Sanyuan Sun, Yun Fan, Jing Li, Xian Luo, Linfang Wang, Yongxin Ren, Weiguo Su. Lancet Respir Med 2021
Times Cited: 38




List of shared articles



Times cited

Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs.
Diego Kauffmann-Guerrero, Amanda Tufman. Curr Opin Oncol 2022
3

The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target.
Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio. J Oncol 2022
4

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
5

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D Ross Camidge, Karin Berghoff, Soetkin Vlassak,[...]. Clin Lung Cancer 2022
4

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
Remi Veillon, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B Cortot, Egbert F Smit, Keunchil Park, Frank Griesinger, Christian Britschgi, Yi-Long Wu,[...]. Clin Lung Cancer 2022
0


Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Juan Bautista Blaquier, Gonzalo Recondo. Drugs Context 2022
0

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting.
Xinghao Ai, Yongfeng Yu, Jun Zhao, Wang Sheng, Jing Bai, Zaiwen Fan, Xuemei Liu, Wenxiang Ji, Rongrong Chen, Shun Lu. Ther Adv Med Oncol 2022
0

Non-small cell lung cancer in China.
Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou. Cancer Commun (Lond) 2022
1


Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
Gillianne G Y Lai, Robin Guo, Alexander Drilon, Daniel Shao Weng Tan. Cancer Treat Rev 2022
1


Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
Myung-Ju Ahn, Marvin Jonne L Mendoza, Nick Pavlakis, Terufumi Kato, Ross A Soo, Dong-Wan Kim, Chong Kin Liam, Te-Chun Hsia, Chee Khoon Lee, Thanyanan Reungwetwattana,[...]. Clin Lung Cancer 2022
1

MET alterations in advanced pulmonary sarcomatoid carcinoma.
Chen Gong, Huihua Xiong, Kai Qin, Jianhua Wang, Yi Cheng, Jing Zhao, Jing Zhang. Front Oncol 2022
0

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.
Fedor Moiseenko, Alexey Bogdanov, Vitaliy Egorenkov, Nikita Volkov, Vladimir Moiseyenko. Curr Treat Options Oncol 2022
0

Meeting an un-MET need: Targeting MET in non-small cell lung cancer.
Elena Michaels, Christine M Bestvina. Front Oncol 2022
0

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study.
Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, Yulan Sun,[...]. Ther Adv Med Oncol 2022
0

Oncogene alterations in non-small cell lung cancer-have we MET a new target?
Wolfram C M Dempke, Susanne Reuther, Zohdy Hamid, Nils H Thoennissen. Transl Lung Cancer Res 2022
0